Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Nyxoah SA (NYXH : NSDQ)

• Company Description    Nyxoah SA is a medical technology company. It focused on the development and commercialization of solutions to treat Obstructive Sleep Apnea. Nyxoah SA is based in Belgium. Number of Employees: 184

• Price / Volume Information    Yesterday's Closing Price: $7.77 Daily Weekly Monthly 20 Day Moving Average: 33,591 shares Shares Outstanding: 34.06 (millions) Market Capitalization: $264.65 (millions) Beta: 1.62 52 Week High: $11.87 52 Week Low: $5.55 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 1.30% -3.20% 12 Week 26.34% 7.91% Year To Date -2.88% -9.03%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL RUE EDOUARD BELIN 12 - MONT-SAINT-GUIBERT,C9 1435 BEL ph: 321-022-2355 fax: 321-045-9075 ir@nyxoah.com http://www.nyxoah.com

• General Corporate Information    Officers Olivier Taelman - Chief Executive Officer Robelga SRL - Chairman John Landry - Chief Financial Officer Kevin Rakin - Director Pierre Gianello - Director Peer Information Nyxoah SA (HLIS) Nyxoah SA (AZTA) Nyxoah SA (APYI) Nyxoah SA (RNVA) Nyxoah SA (HMSY) Nyxoah SA (LRSI) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MEDICAL INFO SYS Sector: Medical CUSIP: B6S7WD106 SIC: 3841 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/25 Next Expected EPS Date: 08/05/25 Share - Related Items Shares Outstanding: 34.06 Most Recent Split Date: (:1) Beta: 1.62 Market Capitalization: $264.65 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.54 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-2.41 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 4.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/05/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 2.71 Price/Cash Flow: - Price / Sales: 56.46 EPS Growth vs. Year Ago Period: -40.00% vs. Previous Quarter: -28.57% Sales Growth vs. Year Ago Period: -15.61% vs. Previous Quarter: -16.93% ROE 06/30/25 - - 03/31/25 - -63.37 12/31/24 - -54.60 ROA 06/30/25 - - 03/31/25 - -46.67 12/31/24 - -41.28 Current Ratio 06/30/25 - - 03/31/25 - 3.59 12/31/24 - 4.56 Quick Ratio 06/30/25 - - 03/31/25 - 3.35 12/31/24 - 4.34 Operating Margin 06/30/25 - - 03/31/25 - -1,571.39 12/31/24 - -1,287.92 Net Margin 06/30/25 - - 03/31/25 - -1,571.39 12/31/24 - -1,287.92 Pre-Tax Margin 06/30/25 - - 03/31/25 - -1,529.93 12/31/24 - -1,248.26 Book Value 06/30/25 - - 03/31/25 - 2.87 12/31/24 - 3.60 Inventory Turnover 06/30/25 - - 03/31/25 - 0.30 12/31/24 - 0.33 Debt-to-Equity 06/30/25 - - 03/31/25 - 0.22 12/31/24 - 0.19 Debt-to-Capital 06/30/25 - - 03/31/25 - 18.33 12/31/24 - 15.82

Powered by Zacks Investment Research ©